Snapshot from Jul 07, 2026 at 01:18 UTC. For live data and tracking: View Live
Entities / European Union — European Medicines Agency / GT Biopharma

European Union — European Medicines Agency & GT Biopharma

1 shared events · Importance 3 · Last updated May 27, 2026

Importance
3
Shared Events
1
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
Shared Events (1)
67
Business
SERB_Pharmaceuticals acquires Idefirix rights
European Union — European Medicines Agency: The European Union — European Medicines Agency>>> is involved in the approval process for Imlifidase>>>, with a payment contingent on its filing acceptance.
GT Biopharma: GT Biopharma>>> divested the European and MENA rights to Imlifidase for 115 million euros, allowing it to focus on other markets and receive significant payments.
May 19, 2026 · 7 articles
NEWSDESK
Explore this relationship live

Track how European Union — European Medicines Agency and GT Biopharma interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.